170 related articles for article (PubMed ID: 37946354)
1. NLRP3: A Promising Therapeutic Target for Inflammatory Bowel Disease.
Zhang J; Zeng S; Wang P; Chen Y; Zeng C
Curr Drug Targets; 2023; 24(14):1106-1116. PubMed ID: 37946354
[TBL] [Abstract][Full Text] [Related]
2. Targeting NLRP3 Inflammasome in Inflammatory Bowel Disease: Putting out the Fire of Inflammation.
Shao BZ; Wang SL; Pan P; Yao J; Wu K; Li ZS; Bai Y; Linghu EQ
Inflammation; 2019 Aug; 42(4):1147-1159. PubMed ID: 30937839
[TBL] [Abstract][Full Text] [Related]
3. Inflammasome-targeting natural compounds in inflammatory bowel disease: Mechanisms and therapeutic potential.
Xu Q; Sun W; Zhang J; Mei Y; Bao J; Hou S; Zhou X; Mao L
Front Immunol; 2022; 13():963291. PubMed ID: 36090968
[TBL] [Abstract][Full Text] [Related]
4. NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease.
Perera AP; Kunde D; Eri R
Curr Pharm Des; 2017; 23(16):2321-2327. PubMed ID: 28155620
[TBL] [Abstract][Full Text] [Related]
5. Biological functions of NLRP3 inflammasome: A therapeutic target in inflammatory bowel disease.
Song Y; Zhao Y; Ma Y; Wang Z; Rong L; Wang B; Zhang N
Cytokine Growth Factor Rev; 2021 Aug; 60():61-75. PubMed ID: 33773897
[TBL] [Abstract][Full Text] [Related]
6. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors.
Bauer C; Duewell P; Lehr HA; Endres S; Schnurr M
Dig Dis; 2012; 30 Suppl 1():82-90. PubMed ID: 23075874
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic implications of inflammasome in inflammatory bowel disease.
Khatri V; Kalyanasundaram R
FASEB J; 2021 May; 35(5):e21439. PubMed ID: 33774860
[TBL] [Abstract][Full Text] [Related]
8. Inflammasome Regulation: Therapeutic Potential for Inflammatory Bowel Disease.
Xu Q; Zhou X; Strober W; Mao L
Molecules; 2021 Mar; 26(6):. PubMed ID: 33808793
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of carboxyamidotriazole on 2,4,6-trinitrobenzene sulfonic acid-induced colitis model is associated with the inhibition of NLRP3 inflammasome and NF-κB activation.
Du X; Chen W; Wang Y; Chen C; Guo L; Ju R; Li J; Zhang D; Zhu L; Ye C
Int Immunopharmacol; 2017 Apr; 45():16-25. PubMed ID: 28152446
[TBL] [Abstract][Full Text] [Related]
10. Probiotics alleviate inflammatory bowel disease in mice by regulating intestinal microorganisms-bile acid-NLRP3 inflammasome pathway.
Liu Z; Wang H
Acta Biochim Pol; 2021 Oct; 68(4):687-693. PubMed ID: 34648252
[TBL] [Abstract][Full Text] [Related]
11. Activation of NLRP3 Inflammasome in Inflammatory Bowel Disease: Differences Between Crohn's Disease and Ulcerative Colitis.
Lazaridis LD; Pistiki A; Giamarellos-Bourboulis EJ; Georgitsi M; Damoraki G; Polymeros D; Dimitriadis GD; Triantafyllou K
Dig Dis Sci; 2017 Sep; 62(9):2348-2356. PubMed ID: 28523573
[TBL] [Abstract][Full Text] [Related]
12. [NLRP3 inflammasome as causative and protecting factor in pathogenesis of inflammatory bowel diseases].
Świerczyński M; Fichna J
Postepy Biochem; 2021 Mar; 67(1):44-53. PubMed ID: 34378904
[TBL] [Abstract][Full Text] [Related]
13. [Inflammatory bowel diseases and inflammasome].
Kim JM
Korean J Gastroenterol; 2011 Dec; 58(6):300-10. PubMed ID: 22198227
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of NLRP3 attenuates sodium dextran sulfate-induced inflammatory bowel disease through gut microbiota regulation.
Wang SL; Zhang MM; Zhou H; Su GQ; Ding Y; Xu GH; Wang X; Li CF; Huang WF; Yi LT
Biomed J; 2023 Oct; 46(5):100580. PubMed ID: 36758943
[TBL] [Abstract][Full Text] [Related]
15. The Pathogenic Role of NLRP3 Inflammasome Activation in Inflammatory Bowel Diseases of Both Mice and Humans.
Liu L; Dong Y; Ye M; Jin S; Yang J; Joosse ME; Sun Y; Zhang J; Lazarev M; Brant SR; Safar B; Marohn M; Mezey E; Li X
J Crohns Colitis; 2017 Jun; 11(6):737-750. PubMed ID: 27993998
[TBL] [Abstract][Full Text] [Related]
16. Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease.
Chen QL; Yin HR; He QY; Wang Y
Biomed Pharmacother; 2021 Jun; 138():111442. PubMed ID: 33667791
[TBL] [Abstract][Full Text] [Related]
17. Role of NLRP3 inflammasome in inflammatory bowel diseases.
Tourkochristou E; Aggeletopoulou I; Konstantakis C; Triantos C
World J Gastroenterol; 2019 Sep; 25(33):4796-4804. PubMed ID: 31543674
[TBL] [Abstract][Full Text] [Related]
18. BAFF Blockade Attenuates DSS-Induced Chronic Colitis
Zhang Y; Tao M; Chen C; Zhao X; Feng Q; Chen G; Fu Y
Front Immunol; 2022; 13():783254. PubMed ID: 35320937
[TBL] [Abstract][Full Text] [Related]
19. Antagonizing interleukin-5 receptor ameliorates dextran sulfate sodium-induced experimental colitis in mice through reducing NLRP3 inflammasome activation.
Ou Y; Yang Z; Zhou Y; Yue H; Hua L; Liu Z; Lin G; Cai H; Chen Y; Hu W; Sun P
Eur J Pharmacol; 2024 Feb; 965():176331. PubMed ID: 38220140
[TBL] [Abstract][Full Text] [Related]
20. The Nlrp3 inflammasome: contributions to intestinal homeostasis.
Zaki MH; Lamkanfi M; Kanneganti TD
Trends Immunol; 2011 Apr; 32(4):171-9. PubMed ID: 21388882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
